M
M. A. Nauck
Researcher at University of Copenhagen
Publications - 22
Citations - 2539
M. A. Nauck is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Incretin & Glucagon-like peptide-1. The author has an hindex of 16, co-authored 22 publications receiving 2442 citations.
Papers
More filters
Journal ArticleDOI
Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
TL;DR: Together with the stimulation of insulin and the inhibition of glucagon secretion, this effect probably contributes to the blood glucose-lowering action of GLP-1-(7-36) amide in type 2-diabetic patients when studied after meal ingestion.
Journal ArticleDOI
Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide.
TL;DR: It is concluded that dipeptidyl peptidase IV is important in GIP metabolism in humans in vivo, and that an N-terminally directed assay is required for determination of plasma concentrations of biologically active GIP.
Journal ArticleDOI
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
TL;DR: Factors are identified that may determine individual incretin secretory responses and explain some of the variations in published findings of group differences in GLP-1 responses to nutrient intake that do not support the contention of a generalised defect in nutrient-related GLp-1secretory responses in type 2 diabetes patients.
Journal ArticleDOI
Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia
Juris J. Meier,Baptist Gallwitz,Nina Siepmann,Jens J. Holst,Carolyn F. Deacon,Wolfgang E. Schmidt,M. A. Nauck +6 more
TL;DR: Glucagon secretion is dose-dependently stimulated by GIP at basal glucose concentrations, and this results underline differences between GIP and the glucagonostatic incretin GLP-1.
Journal ArticleDOI
Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans
Juris J. Meier,Arnica Gethmann,O. Götze,Baptist Gallwitz,Jens J. Holst,Wolfgang E. Schmidt,M. A. Nauck +6 more
TL;DR: GLP-1 improves postprandial lipidaemia, presumably as a result of delayed gastric emptying and insulin-mediated inhibition of lipolysis, and may reduce the cardiovascular risk in patients with type 2 diabetes.